- Trials with a EudraCT protocol (10,507)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10,507 result(s) found for: Blood Disease.
Displaying page 97 of 526.
EudraCT Number: 2011-002384-16 | Sponsor Protocol Number: TTD-11-01/AXI-IIG-01 | Start Date*: 2011-09-21 | |||||||||||
Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD) | |||||||||||||
Full Title: A Phase II study of Axitinib as maintenance for patients with advanced colorectal carcinoma. | |||||||||||||
Medical condition: Advanced colorectal carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002106-52 | Sponsor Protocol Number: CANBiS-AD | Start Date*: 2020-03-19 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer's disease patients with BPSD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001603-37 | Sponsor Protocol Number: AC-055G203 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:ACTELION Pharmaceuticals Ltd | |||||||||||||
Full Title: A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction and... | |||||||||||||
Medical condition: Heart failure with preserved ejection fraction and pulmonary vascular disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002390-25 | Sponsor Protocol Number: E21-04 | Start Date*: 2022-01-20 | |||||||||||
Sponsor Name:Fab'entech | |||||||||||||
Full Title: A two-stage randomized, placebo-controlled, double-blind, phase 2a study to characterize the safety and pharmacokinetics of FBR-002 in patients hospitalized with COVID-19 need of supplemental oxyge... | |||||||||||||
Medical condition: COVID-19 in hospitalized patients in need of supplemental oxygen and at risk of severe outcome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004613-24 | Sponsor Protocol Number: 01 | Start Date*: 2016-05-30 |
Sponsor Name:Radboudumc | ||
Full Title: Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized double-blind placebo-controlled trial. | ||
Medical condition: (very early) systemic sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002176-27 | Sponsor Protocol Number: HC-G-H-1505 | Start Date*: 2017-08-30 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
Full Title: Pragmatic, prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of a 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution ... | |||||||||||||
Medical condition: Hypovolaemia due to acute blood loss in trauma surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) NL (Completed) ES (Restarted) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021590-37 | Sponsor Protocol Number: A4061058 | Start Date*: 2011-01-03 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017,USA | |||||||||||||
Full Title: A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAI... | |||||||||||||
Medical condition: Hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022382-10 | Sponsor Protocol Number: CCX114151 | Start Date*: 2011-01-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease | |||||||||||||
Medical condition: Subjects with Moderately-to-Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) CZ (Completed) SE (Prematurely Ended) NO (Completed) BE (Completed) DK (Completed) HU (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003296-35 | Sponsor Protocol Number: CINC424G12201 | Start Date*: 2019-09-19 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cel... | ||||||||||||||||||
Medical condition: chronic graft versus host disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) IT (Completed) CZ (Completed) LT (Completed) GR (Completed) ES (Ongoing) SI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001121-14 | Sponsor Protocol Number: CL010_168 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculi... | |||||||||||||||||||||||
Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IE (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed) CZ (Completed) NL (Completed) ES (Completed) HU (Completed) DK (Completed) BE (Completed) NO (Completed) FR (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005301-19 | Sponsor Protocol Number: 20060579 | Start Date*: 2009-06-09 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KR... | |||||||||||||
Medical condition: Second-line treatment of KRAS mutant-type metastatic colorectal cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024023-25 | Sponsor Protocol Number: Nefrovid2010 | Start Date*: 2011-09-22 | |||||||||||
Sponsor Name:Lorenzo Victor, PhD | |||||||||||||
Full Title: An open label, parallel groups, phase III, clinical trial to assess the antiproteinuric effects of the vitamin D derivates in patients with chronic kidney disease and vitamin D insufficiency. | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002022-41 | Sponsor Protocol Number: CHAGAS-EVOL I | Start Date*: 2011-10-13 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Ramón y Cajal | |||||||||||||
Full Title: Assessment of Therapeutic Response to Benznidazole in patients with Chronic Chagas Disease by Measuring Plasma Parasite Load and the Specific Immune Response against Trypanosoma cruzi. A Randomized... | |||||||||||||
Medical condition: Chagas disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004842-40 | Sponsor Protocol Number: IG1309 | Start Date*: 2014-05-09 | |||||||||||
Sponsor Name:Instituto Grifols S.A. | |||||||||||||
Full Title: Pilot study to evaluate the effect of plasma exchange in motor and cognitive function in patients with amyotrophic lateral sclerosis | |||||||||||||
Medical condition: Amytrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002823-16 | Sponsor Protocol Number: 02-2011 | Start Date*: 2011-07-27 | |||||||||||
Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA | |||||||||||||
Full Title: Effects of Vitamin D in patients affected by heart failure | |||||||||||||
Medical condition: Heart failure is a condition that occurs when the heart loses its normal ability to pump blood to maintain vital body functions and, therefore, works with lower efficiency. Several studies have sho... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003454-41 | Sponsor Protocol Number: ACE-536-MDS-001 | Start Date*: 2016-05-10 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, Double-Blind, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Placebo For The Treatment Of Anemia Due To IPSS-R Very Low, Low, Or Intermediate Risk M... | |||||||||||||
Medical condition: Subjects with ring sideroblasts who require regular Red Blood Cell (RBC) Transfusions due to anemia due to Myelodysplastic Syndromes (MDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) NL (Completed) BE (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017306-36 | Sponsor Protocol Number: TIGER | Start Date*: 2010-11-19 | |||||||||||
Sponsor Name:Leiden University Medical Center, Department of Rheumatology | |||||||||||||
Full Title: ANTI-IGE THERAPY (OMALIZUMAB) IN IGE-ACPA POSITIVE RA. | |||||||||||||
Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005680-25 | Sponsor Protocol Number: C/22/2011 | Start Date*: 2012-04-24 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer pati... | |||||||||||||
Medical condition: Locally advanced or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003009-88 | Sponsor Protocol Number: DU176b-E-U210 | Start Date*: 2012-12-27 | |||||||||||
Sponsor Name:Daiichi Sankyo Development Ltd | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-CENTER STUDY OF ADDING EDOXABAN OR CLOPIDOGREL TO ASPIRIN TO MAINTAIN PATENCY IN SUBJECTS WITH PERIPHERAL ARTERIAL DISEASE FOLLOWING FEMOROPOPLIT... | |||||||||||||
Medical condition: Edoxaban is being investigated for use in PAD subjects after femoropopliteal endovascular interventions with/without stent placement for the maintenance of patency and prevention of re-intervention. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) NL (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003359-35 | Sponsor Protocol Number: GAU-CL-202 | Start Date*: 2007-12-19 |
Sponsor Name:Amicus Therapeutics, Inc. | ||
Full Title: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF AT2101 IN TREATMENT-NAIVE ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASE | ||
Medical condition: Type 1 Gaucher Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
